Using HO-1 induction and inhibition/depletion strategies, cumulative evidence, over the past decade, has convincingly demonstrated a beneficial effect of HO-1 activity in clinical and experimental kidney disease, including ischemia-reperfusion injury [77], glomerular and interstitial inflammation [78], nephrotoxin- or angiotensin II-induced injury [79], kidney transplantation [80], and diabetic nephropathy [81,82]. Here, HMOX1 is linked to kidney disorder.